



## DAFTAR PUSTAKA

- Acosta, B.S., Grimsley, E.W. 1999. Zidovudin-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. *South.med J.* 92:421-423
- Acosta, E.P., Fletcher, C.V. 1996. Clinical pharmacokinetics of zidovudin. An update. *Clin. Pharmacokinet.* 30:251-261
- Adane, A., Desta, K., Bezabih, A., Gashaye A., Kassa, D. 2012. HIV-associated anaemia before and after initiation of antiretrovirus therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia. *Ethiopian Medical Journal* 2012 Jan. 50:13–21
- Al-Jabri, A.A. 2007. Review: Mechanism of Host Resistance Against HIV Infection and Progression to AIDS. *Sultan Qaboos University Journal.* 2007. 7:82-86
- Akinbami, A., Oshinaike, O., Adeyemo, T., Adediran, A., Owolabi, D., Dada, M., et al. 2010. Hematologic Abnormalities in Treatment-Naive HIV Patients. *Infectious Disease: Research and Treatment* 2010.3:45-49 doi 10.4137/IDRT.S6033. <http://www.la-press.com>. Diakses: 3/9/2015
- Anderson, J.E. 1999. Allogenic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas, ED, Blume KG, Forman SJ, eds. *Hematopoietic Cell Transplantation*. Malden, MA: Blackwell Science: 872-886
- Argawal, D., Chakravarty, J., Chaube, L., Rai, M., Argawa, N.R., Sundar, S. 2009. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. *Indian J Med.* 132, pp: 386 - 389
- Assefa, M., Abegaz, W.E., Shewamare, A., Medhin, G., Belay, M. 2015. Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia. *BMC Hematology*. 15:6
- Ayers, K.M., Clive, D., Tucker, W.E., Hajian, G., & de Miranda, P. (1996a). Nonclinical toxicology studies with zidovudine: Genetic toxicity test and carcinogenicity bioassays in mice and rats. *Fundam.appl.Toxicol.* 32:148-158
- Ayers, K.M., Tucker W.E., Hajian, G., & de Miranda, P. (1996b). Nonclinical toxicology studies with zidovudine: Acute, subacute, and chronic toxicity in rodents, dogs, and monkeys. *Fundam.appl. Toxicol.* 32:129-139



Azevedo-Pereira J.M., Moniz-Pereira J., Santos-Costa, Q.2005.HIV-2 infection and chemokine receptor usage clues to reduced virulence of HIV-2.Curr. HIV Res. 2005. 3: 3-16.

Balwedeg, T., Riccio, M., Gruzelier, J., Hawkins, D., Burgess, A., Irving, G., et al. Neurophysiological evaluation of zidovudin in symptomatic HIV-1 infection: Alongitudinal placebo-controlled study. *J.neurol. Sci.*132:162-169

Campbell, T.B., Smeaton, L.M., Kumarasamy, N., Flanigan, T., Klingman, K.L., Firnhaber, C, et al. Efficacy and Safety of three antiretrovirus Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multi national Settings. *PLOS Medicine*. 2012.9:100-129

Centers for Disease Control and Prevention, 2014. About HIV/AIDS: What Are The Stages of HIV. <http://www.cdc.gov/hiv/basics/whatishiv.html>. Diakses: 5/8/2015.

Cicconi, P., Lepri, A.C., Castagna, A. 2010. Insight into reasons for discontinuations according to a year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretrovirus - naive patients HIV.11: 104-13.

Coster, L.O., Kumar, P.N. 2012. Contemporary Role of Nevirapine in HIV Treatment. *Goergetown University Medical Center* 2012. 14:132-4

Cutler, C.S., Stephanie, J., Greenberg, P.H., Deeg, H.J., Perez, W.S., Anasetti, C., et al.2015. A decision analysis of allogeneic bone marrow transplantation for the myelodysplasia syndrome: delayed transplantation for low risk myelodysplasia is associated with improved outcome. *Blood journal*.104

daCosta, A.M., Seiceira, R.C., Rodrigues, C.R., Hoffmeister, C.R.D., Cabral, L.M., Rocha, H.V.A. 2013. Evafirenz Dissolution Enhanchement I: Co-Micronization. *mdpi journal*.1-22

Dauval, X., Journot, V., Leport, C., Chene, G., Dupon, M., Cuzin, L., et al. 2004. Antiprotease Cohort (APROCO) Study Group: Incidence of HIV of and risk faktor for adverse drug reactions in a prospective cohort of HIV Infected adults initiating protease inhibitor containing therapy. *Infectious Dis Soc Am*. 2004. 39 :248-255.

deBenoist, B.E.M., Egli, I., Cogswell, M., Handbook WHO. 2008. Geneva, Switzerland, WHO. World Wide Prevalence of Anaemia 1993-2005.



- Eluwa, G.I., Badru, T., Akpoigbe, K.J. 2012. Adverse drug reactions to antiretrovirus therapy (ARVs): Incidence, type and risk factors in Nigeria. *Clinical Pharmacology*. [www.biomedcentral.com/1472-6904/12/7](http://www.biomedcentral.com/1472-6904/12/7). Diakses: 25/6/2015
- Elzi, L., Marzolini, C., Furre, H. 2008. Treatment modification in human immunodeficiency virus infected individuals starting combination antiretrovirus therapy between 2005 and 2008. *Arch Intern Med.* 2010. 170:57-65.
- Ferede, G. & Wondimeneh, Y. 2013. Prevalence and related factors of anemia in HAART-NAIVE HIV positive patients at Gondar University Hospital, Northwest Ethiopia. *BMC Hematology*. 13:8 <http://biomedcentral.com/2051-1839/13/8>. Diakses: 3/9/2015.
- Health and Human Services Panel on Antiretrovirus Guidelines for Adults and Adolescents. 2012. Guidelines for the use of antiretrovirus agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: <http://aidsinfo.nih.gov/contentfiles/adultadolescentgl.pdf>. Diakses: 3/9/2015.
- Jialun, Z., Jaquet, A., Bissagnene, E., Musick, B., Kaloustian, K.W., Maxwell, N., et al. 2012. Short-term risk of anaemia following initiation of combination antiretrovirus treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. *Journal of the International AIDS Society*. 15:5
- Kementerian Kesehatan Republik Indonesia. 2011. Tatalaksana Klinis Infeksi HIV dan Terapi Antretroviral pada orang dewasa. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. 616.979
- Kementerian Kesehatan Republik Indonesia. 2014. Laporan Statistik Kasus HIV/AIDS di Indonesia, sampai Juni 2014. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan
- Kumar, A.K.H., Ramachandran, G., Rajasekaran, S., Padmapriyadarsini, C., Narendran, G., Anitha, S., et al. 2009. Pharmacokinetics of lamivudine & stavudine in generic fixed dose combination in HIV-1 infected adults in India. *Indian J.Med* 2009. 451-457
- Levy, L.A. 1993. Microbiological Reviews. Departement of Microbiology. Mount Sinai School of Medicine. 2: 87-91



- Lichtenstein, K.A., Armon, C., Buchacz, K., Chmiel, J.S., Moorman, A.C., Wood, K.C., et al. 2008. Initiation of antiretrovirus therapy at CD4 cell counts  $\geq$  350 cells/mm<sup>3</sup> does not increase incidence or risk of peripheral neuropathy, anemia or renal insufficiency. *Journal Acquir Immune Defic Syndr.* 47.
- Luma, H.N., Doualla, M.S., Choukem, S.P., Temfack, E., Ashuntantang, G., Joko, H.A., et al. 2012. Adverse drug reactions of Highly active antiretrovirus Therapy (HAART) in HIV infected patients at General Hospital, Douala, Cameroon: a cross sectional study. *Pan African Medical Journal.* 19:37-8688
- Masaisa, F., Gahutu, J.B., Mukibi, J., Delanghe, J. & Philippe, J. 2011. Anemia in Human Immunodeficiency Virus-Infected and Uninfected Women in Rwanda. The American Society of Tropical Medicine and Hygiene. *Am. J. Trop. Med. Hyg.* 84:456-460 doi: 10.4269/ajtmh.2011.10-0519
- McEvoy, M.T., Shander, A. 2013. Anemia, Bleeding, and blood transfusion in the Intensive Care Unit: Causes, Risk, Costs, and New Strategies. *American Journal of Critical Care* 2013. 22.
- Michael, T., Shander, A. 2013. Anemia, Bleeding, and Blood Tranfusion in The Intensive Care Unit: Causes, Risk, Costs, and New Strategies. *AJCC*. 22: eS1-eS14
- Mihiretie, H., Taye, B., Tsegaye, A. 2015. Magnitude of Anemia and Associated Factors among Pediatric HIV/AIDS Patients Attending Zewditu memorial hospital ART Clinic, Addis Ababa, Ethiopia. Hindawi Publishing Corporation Anemia Volume 2015.479329.6.<http://dx.doi.org/10.1155/2015/479329>
- Moore, R.D., Keruly, J.C., Chaisson, R.E. 1998. Anemia and Survival in HIV Infection. *Journal of AIDS and Human Hematology*. 19:29-33
- Munyazesa, E., Emile, I., Mutimura, E. et al. 2012. Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: a cross-sectional study *BMJ Open*. *BMJ*. 2:e001600.doi:10.1136
- Ndlovu, Z., Chirwa, T., Takuva, S. 2010. Incidence and predictors of recovery from anaemia within an HIV-infected South African Cohort, 2004-2009. *Pan African Medical Journal* 2010.
- Nigam, J.S., Bharti, J.N., Kumar, D., Sharma, A. 2013. A Comparison of Hemoglobin A<sub>2</sub> levels in untreated and treated groups of HIV patients on ART including Zidovudine. 828214,3.<http://dx.doi.org/10.1155/2013/828214>



Noble, R. 2009. Introduction to HIV types, groups and subtypes. Accesed June 24, 2009. <http://www.avert.org/hiv-types.htm>. Diakses: 8/6/2015

Nowrouzian, M.R. 2008. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Scientific and Clinical Aspects of Anemia in Cancer 2nd, Revised and Enlarged Edition 2008. Center, University Hospital of Essen, Essen, Germany, 117-123.

O'Brien, M.E., Clark, R.A., Besch, C.L. 2003. Patterns and correlates of discontinuation of the initial HAART regimen in urban outpatient cohort. *J Acquir Immune Defic Syndr*. 2003;34: 407-14

Owiredu, W.K.B., Quaye, L., Amidu, N., & Mensah, O.A. 2011. Prevalence of anaemia and immunological markers among Ghanaian HAART-HIV- patients and those on HAART. *African Health Sciences*. 11: 2–15.

Pedoman Tatalaksana Infeksi HIV Pada Anak dan Terapi. [http://pppl.depkes.go.id.asset.regulasi/100.Permenkes\\_20.No\\_2021.Tahun\\_2013.Penanggulangan\\_HIV/AIDS](http://pppl.depkes.go.id.asset.regulasi/100.Permenkes_20.No_2021.Tahun_2013.Penanggulangan_HIV/AIDS).

Miedani, M., Rezaei, F. Maracy, M.R., Avijgan, M., Tayeri, K. 2012. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. *Journal Med Sci*. 2012 Feb; 17: 138-142

Mihanović, M.P., Haque, N.S., Rutherford, G.W., Zekan, Š, & Begovac. 2013. Toxicity-related antiretrovirus drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. *Medical Science Monitor : International Medical Journal of Experimental and Clinical Research*. 19:483–92. <http://doi.org/10.12659/MSM.889283>. Diakses : 9/6/2015.

Phe, T., Thai, S., Veng, C., Sok, S., Lynen, L., & van Griensven, J. 2013. Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudin for Stavudin in HIV-Infected Adult Patients on Antiretrovirus Treatment. *PLoS ONE*. 2013;8:1–7. <http://doi.org/10.1371/journal.pone.0060206>. Diakses: 4/3/2015.

Subbaraman, R., Devaleenal, B., Selvamuthu, P., Yeathom, T., Solomon, S.S., Mayer, K.H., et al. 2015. Factors Associated with Anemia in HIV-infected Individuals in Southern India. *Int J STD AIDS*. 20: 489-492.

Tefferi, A. 2003. Anemia in adults: a contemporary approach to diagnosis. *Mayo Clin Proc*. 78: 1274-1280.



United Nations Programme on HIV/AIDS (UNAIDS). 2011. UNAIDS Terminology Guidelines. United Nations Programme on Human Immunodeficiency Virus

United Nations Programme on HIV/AIDS (UNAIDS). 2014. Fast-Track ending the AIDS epidemic. United Nations Programme on Human Immunodeficiency Virus

Volberding, P.A., Levine, A.M., Dieterich, D., Mildvan, D., Mitsuyasu, R., Saag, M. 2004. Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies. *Oxford journal.* 38: 1454 - 1463.

Von Wyl, V., Yerly, S., Boni, J., Burgisser, P., Klimkait, T., Battegay, M., et al. Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with combination Antiretrovirus Therapy Containing Tenofovir.

World Health Organization, The United Nations Children's Fund, United Nations University. 2001. Iron deficiency anaemia: assessment, prevention and control. a guide for programme managers. Geneva, World Health Organization.

World Health Organizatin. 2007. Assessing the iron status of populations: report of joint World Heath Organization/ Centers for Disease Control and Prevention technical consultation on the assessment of iron status at the population level. 2nded, Geneva, World Health Organization.

World Health Organization. 2010. Handbook for guidline developmment. Geneva. World Health Organization, March 2010

World Health Organizatin, 2014. HIV/AIDS [cited 2014 Sept 14]. Available from: <http://www.who.int/mediacentre/factsheets/fs360/en/>. Diakses: 8/6/2015.

Williams, B.G., Korenromp, E.L., Gouws, E., Schmid G.P., Auvert, B., & Dye, C.2006.HIV infection, antiretrovirus therapy, and CD4+ cell count distributions in African populations. *The Journal of Infectious Diseases.* <http://doi.org/ 10.1086/508206>. Diakses: 4/5/2015.

Zhou, J., Jaque, A., Bissagnene, E., Musick, B., Kaloustian, K., Maxwell, N., et al. 2012. Short-term risk of anaemia following initiation combination antiretrovirus treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pasific, and central and South America. *Journal of the International AIDS Society.*15;5